Key facts
- FosunKairos’s last known valuation is $401.4M (Dec 2025).
- It has raised $91.5M; the latest was Later Stage VC ($91.5M) in Dec 2025.
- Notable investors include Shenzhen Pingshan Guidance Fund Investment.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for FosunKairos
- ·The full record, as it builds
Funding rounds
No funding rounds for FosunKairos are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FosunKairos
Developer of immune cell therapy products committed to providing innovative pharmaceuticals to treat cancer patients. The company through its well-established research wing researches and develops tumor immune cell therapy and kite-439 products, aiming to produce quality medicines for medical industry clients for the treatment of B-cell lymphomas and leukemias.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Employees
- 22
- Website
- fosunkairos.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
FosunKairos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FosunKairos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FosunKairos in its N-PORT filings yet. We sweep new filings monthly.